TY - JOUR
T1 - Clear-cell Renal Cell Carcinoma
T2 - Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors
AU - Verbiest, Annelies
AU - Renders, Inne
AU - Caruso, Stefano
AU - Couchy, Gabrielle
AU - Job, Sylvie
AU - Laenen, Annouschka
AU - Verkarre, Virginie
AU - Rioux-Leclercq, Nathalie
AU - Schöffski, Patrick
AU - Vano, Yann
AU - Elaidi, Reza Thierry
AU - Lerut, Evelyne
AU - Albersen, Maarten
AU - Oudard, Stéphane
AU - Fridman, Wolf Hervé
AU - Sautès-Fridman, Catherine
AU - Albigès, Laurence
AU - Wozniak, Agnieszka
AU - Zucman-Rossi, Jessica
AU - Beuselinck, Benoit
N1 - Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - In advanced clear-cell renal cell carcinoma, the Checkmate214 study showed superior outcomes with ipilimumab-nivolumab in International Metastatic RCC Database Consortium intermediate-/poor-risk patients and with sunitinib in good-risk patients. We demonstrate how underlying molecular subtypes and angiogenic gene expression can explain these differences and can characterize the heterogeneous International Metastatic RCC Database Consortium intermediate-risk group.
AB - In advanced clear-cell renal cell carcinoma, the Checkmate214 study showed superior outcomes with ipilimumab-nivolumab in International Metastatic RCC Database Consortium intermediate-/poor-risk patients and with sunitinib in good-risk patients. We demonstrate how underlying molecular subtypes and angiogenic gene expression can explain these differences and can characterize the heterogeneous International Metastatic RCC Database Consortium intermediate-risk group.
KW - Angiogenesis
KW - Biomarker
KW - Immune checkpoint inhibitor
KW - Molecular subtype
KW - Sunitinib
UR - http://www.scopus.com/inward/record.url?scp=85067352180&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2019.05.009
DO - 10.1016/j.clgc.2019.05.009
M3 - Article
C2 - 31229459
AN - SCOPUS:85067352180
SN - 1558-7673
VL - 17
SP - e981-e994
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 5
ER -